{"disease":{"id":"tumor-mutation-burden","name":"tumor mutation burden"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03683407","title":"Effect of Chemotherapy on TMB in NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Baodong Qin","has_results":false},{"nct_id":"NCT04098068","title":"Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}